Evidence-Based Drug Policy Act of 2025
USA119th CongressHR-3082| House
| Updated: 4/29/2025
Dina Titus
Democratic Representative
Nevada
Cosponsors (1)
Judiciary Committee, Energy and Commerce Committee, Oversight and Government Reform Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
This legislation proposes to repeal Section 704(b)(12) of the Office of National Drug Control Policy Reauthorization Act of 1998. This specific section, codified as 21 U.S.C. 1703(b)(12), currently prohibits the use of federal funds for programs that provide sterile needles or syringes for illegal drug use, and restricts the Office of National Drug Control Policy (ONDCP) from endorsing such initiatives. By eliminating this provision, the bill aims to remove a significant federal barrier to funding and supporting harm reduction strategies. This legislative action could enable federal resources to be directed towards initiatives like needle exchange programs, potentially improving public health outcomes and reducing disease transmission among individuals who use drugs.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Oversight and Government Reform, and in addition to the Committees on Energy and Commerce, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Crime and Law Enforcement
Evidence-Based Drug Policy Act of 2025
USA119th CongressHR-3082| House
| Updated: 4/29/2025
This legislation proposes to repeal Section 704(b)(12) of the Office of National Drug Control Policy Reauthorization Act of 1998. This specific section, codified as 21 U.S.C. 1703(b)(12), currently prohibits the use of federal funds for programs that provide sterile needles or syringes for illegal drug use, and restricts the Office of National Drug Control Policy (ONDCP) from endorsing such initiatives. By eliminating this provision, the bill aims to remove a significant federal barrier to funding and supporting harm reduction strategies. This legislative action could enable federal resources to be directed towards initiatives like needle exchange programs, potentially improving public health outcomes and reducing disease transmission among individuals who use drugs.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Oversight and Government Reform, and in addition to the Committees on Energy and Commerce, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Dina Titus
Democratic Representative
Nevada
Cosponsors (1)
Judiciary Committee, Energy and Commerce Committee, Oversight and Government Reform Committee
Crime and Law Enforcement
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted